Increases of 510 mmHg systolic are common, with peak effect at 4 hours post-dose
Achieve your weight goals with holistic support Your healthcare provider is your best resource when considering Semaglutide or Tirzepatide after gallbladder removal
Semaglutide Label Update Supported by EMA On December 12, Novo Nordisk announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion on updating the label for its blockbuster therapy Ozempic (semaglutide) to include information on reducing the risk of kidney-related events
The ISSA GLP-1 Weight Loss Support Training course equips fitness and wellness professionals to understand these medications, adapt training safely, and coach sustainable behavior change, without overstepping scope of practice
Completing an evaluation does not guarantee a prescription
The ADA guidelines recommend continuing effective glucose-lowering medications as long as they remain beneficial and well-tolerated, with reassessment approximately every 3 months until glycemic targets are achieved, then at least twice yearly
